Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) have earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $20.5455.

CMPS has been the subject of several recent analyst reports. Lifesci Capital upgraded Compass Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. Compass Point set a $15.00 price target on Compass Pathways in a research note on Thursday, February 12th. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Compass Pathways in a research note on Tuesday, April 28th. Royal Bank Of Canada upped their price target on Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. Finally, UBS Group set a $18.00 price target on Compass Pathways in a research note on Thursday.

Compass Pathways Stock Performance

CMPS stock opened at $9.91 on Monday. Compass Pathways has a 1-year low of $2.25 and a 1-year high of $10.21. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.77 and a quick ratio of 0.77. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -3.21 and a beta of 2.39. The business has a 50 day simple moving average of $6.86 and a two-hundred day simple moving average of $6.59.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Tuesday, March 24th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.59). Research analysts anticipate that Compass Pathways will post -1.83 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. RTW Investments LP boosted its position in shares of Compass Pathways by 0.6% during the 4th quarter. RTW Investments LP now owns 8,757,390 shares of the company’s stock valued at $60,426,000 after acquiring an additional 50,000 shares during the last quarter. Nantahala Capital Management LLC boosted its position in shares of Compass Pathways by 47.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after acquiring an additional 1,350,698 shares during the last quarter. Millennium Management LLC boosted its position in shares of Compass Pathways by 39.9% during the 3rd quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock valued at $15,562,000 after acquiring an additional 774,090 shares during the last quarter. Toronto Dominion Bank boosted its position in shares of Compass Pathways by 152.9% during the 4th quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after acquiring an additional 1,529,013 shares during the last quarter. Finally, ARK Investment Management LLC boosted its position in shares of Compass Pathways by 1.6% during the 4th quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company’s stock valued at $14,876,000 after acquiring an additional 34,894 shares during the last quarter. 46.19% of the stock is currently owned by institutional investors.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.